[ad_1]
However, the situation in the media market is constantly changing: if you want to support quality business journalism and want to be part of the Portfolio community, subscribe to Portfolio Signature articles. Know more
The health news portal, citing an AstraZeneca spokesperson, said it was “suspending vaccination due to standard review procedure, providing an opportunity to verify safety data.”
The coronavirus vaccine, developed by AstraZeneca and the University of Oxford, is being tested in the United States and the United Kingdom, among others. The health problem occurred in a patient treated in the UK. Stat News said, however, that the patient is expected to recover. The company said in a statement that it was a routine measure.
“Diseases can occur randomly in larger series of experiments, but must be thoroughly investigated from an independent perspective,” the company said. According to the resolution, AstraZeneca will expedite the investigation so that the vaccine authorization procedure is as short as possible. The company added that the goal is only to determine whether the health problem was caused by the vaccine.
AstraZeneca also emphasized that this is a unique case of tens of thousands of participants in the third phase of clinical trials.
The American newspaper The New York Times knows from a well-informed source that the health problem encompasses inflammation of the spine, which can also be caused by a viral infection.
The AZD1222 vaccine, developed by AstraZeneca, is based on an attenuated chimpanzee flu virus that acts on the immune system to kill the coronavirus in the event of infection.
According to Stat News, the suspension of testing will also affect testing of other AstraZeneca vaccines and clinical trials of other vaccine manufacturers.
Nine vaccine manufacturers from the US and Europe assured everyone Tuesday that they would meet safety and efficacy standards. AstraZeneca, Pfizer, GlaxoSmithKline, Johnson & Johnson, Merck & Co, Moderna, Novavax, Sanofi, and BioNTech are committed to respecting the integrity of the scientific process in vaccine development, following growing concerns that safety standards may be compromised under political pressure to accelerate vaccine development. Above all, US President Donald Trump is voicing that by the end of the year, but there may be a vaccine until the presidential election on November 3.
Cover image: Getty Images
[ad_2]
